ArticleProgress in orthodontics2026
DMXAA accelerates orthodontic tooth movement via macrophage-mediated Rab13-enriched extracellular vesicle release and chemokine secretion.
Article in Progress in orthodontics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOrthodontic tooth movement (OTM) is a complex process involving periodontal tissue remodeling, and safe strategies to accelerate OTM remain a research focus. DMXAA (Vadimezan), a non-toxic immune-modulating drug with established clinical trial data, stimulates the secretion of pro-inflammatory cytokines potentially relevant to OTM, which involves immune-mediated bone remodeling. METHODOLOGY: A murine OTM model was established in C57BL/6 mice, receiving local subperiosteal injections of DMXAA. Tooth movement distance, bone volume fraction, and osteoclast parameters were quantified via Micro-CT and histology. The mechanism was dissected using RNA-sequencing of bone marrow-derived macrophages (BMDMs), sEV proteomics, and functional osteoclastogenesis assays. Macrophage depletion and Rab13 knockdown models were employed to verify specificity.
resultsLocal DMXAA administration significantly enhance orthodontic tooth movement and rate in mice under orthodontic force application, accompanied by reduced alveolar bone volume and increased osteoclast numbers on the compressive force side. DMXAA induced macrophage accumulation at the force-applied site, polarizing them toward M1-like pro-inflammatory phenotypes characterized by high secretion of CCL5 and CXCL10. Furthermore, small extracellular vesicles derived from DMXAA-treated macrophages, which were enriched with Rab13 protein, contributed to osteoclast fusion and maturation, thereby accelerating OTM.
conclusionsDMXAA accelerates OTM through a dual mechanism: chemokine-driven osteoclast differentiation and sEV-Rab13-mediated osteoclast fusion. These findings highlight the Rab13-sEV axis as a novel therapeutic target for modulating the periodontal microenvironment and enhancing orthodontic efficiency. Our results elucidated a novel mechanism by which DMXAA accelerated orthodontic tooth movement and suggested it as a potential therapeutic agent to optimize orthodontic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.